MDLN Stock Risk & Deep Value Analysis
Medline Inc
Healthcare • Medical Instruments & Supplies
DVR Score
out of 10
What You Need to Know About MDLN Stock
We analyzed Medline Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MDLN through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
MDLN Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is the continued erosion of profitability. If Q2 2026 gross and net margins continue to decline (e.g., gross margin falling below 24% or net income dropping further year-over-year) despite revenue growth, it suggests a persistent inability to manage costs or pricing pressure, undermining future earnings potential and investor confidence.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Low
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Net income decline of 25.8% YoY in Q1 2026 despite 10.7% revenue growth, indicating significant margin compression.
- ⚠
Gross margin declined from 27.5% to 25.0% YoY in Q1 2026, signaling pricing pressure or increased cost of goods.
- ⚠
Mention of a recent FDA warning letter / related device removal activity, posing potential regulatory and reputational risks.
- ⚠
Significant total debt of $12.76 billion, requiring careful management of cash flows.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (Estimated August 2026): Continued decline in gross or net margins, or revenue growth deceleration below 5% YoY, could lead to significant share price correction.
- 📅
Escalated FDA Action (Ongoing): Further regulatory action or substantial product recalls related to the warning letter could impact reputation and incur significant costs/revenue loss (potential >$100M in Q expenses).
When to Reconsider
- 🚪
Exit if Q2 2026 gross margin falls below 24.0% and shows no clear path to recovery.
- 🚪
Sell if annualized free cash flow drops below $1 billion, indicating potential deterioration of financial health.
- 🚪
Exit if the stock fails to recover above $40.00 within 6 months of its secondary offering, signaling lack of sustained investor interest.
Unlock MDLN Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Medline Inc (MDLN) Do?
Market Cap
$48.74B
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
43,000
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services such as, consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. Medline Inc. was founded in 1966 and is based in Northfield, Illinois.
Visit Medline Inc WebsiteInvestment Thesis
If Medline can successfully leverage its robust distribution network and customer relationships to continue securing substantial new enterprise contracts (>$250M in annualized revenue per year) while simultaneously stabilizing and slightly improving gross margins (e.g., 25-26% sustained), then its current valuation could justify a re-rating towards peer multiples with strong FCF conversion. This is bullish because the market may currently be underestimating its ability to reverse margin compression given its scale and recent IPO premium.
Is MDLN Stock Undervalued?
Unlock the full AI analysis for MDLN
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
MDLN Price Targets & Strategy
12-Month Target
$50.00
Bull Case
$60.00
Bear Case
$30.00
Valuation Basis
Based on a 15x forward EV/EBITDA multiple applied to estimated FY26 Adjusted EBITDA of $3.2B, less net debt of $10.52B, divided by 934.06M estimated shares outstanding, roughly aligning with median analyst target.
Entry Strategy
Consider dollar-cost averaging near the secondary offering price of $37.00, or on any dips towards $35.00, observing for price stability after the offering.
Exit Strategy
Take initial profits at $50.00 (median analyst target), consider full exit at $60.00 (highest analyst target). Implement a stop-loss order if price drops below $30.00 (approximately 20% below current price).
Portfolio Allocation
2% for aggressive risk tolerance, given the limited 10x growth potential and industry maturity.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is MDLN Financially Healthy?
Valuation
P/E Ratio
50.45
Forward P/E
40.22
EV/EBITDA
25.35
PEG Ratio
6.05
Price/Book
2.52
Price/Sales
1.09
Profitability
Gross Margin
25.86%
Operating Margin
7.08%
Net Margin
3.32%
Return on Equity
6.89%
Revenue Growth
8.10%
EPS
$1.19
Balance Sheet
Current Ratio
4.29
Quick Ratio
2.37
Debt/Equity
1.17
Total Debt
$12.76B
Cash & Equivalents
$2.24B
Cash Flow
Operating Cash Flow
$1.44B
Free Cash Flow
$1.01B
EBITDA
$3.49B
Other
Beta (Volatility)
1.17
Does MDLN Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
4 Identified
Medline's moat is durable due to the significant capital investment required for its vast distribution network and manufacturing capabilities, which are difficult to replicate. Switching costs for healthcare providers, ingrained in procurement systems and established supply chains, also provide a competitive barrier. However, the low-margin nature of the business and intense competition from large rivals cap the extent of moat expansion.
Moat Erosion Risks
- •Intensifying price competition from large rivals (e.g., Cardinal Health, McKesson) leading to further gross margin erosion.
- •Disruptions in global supply chains or significant increases in raw material/transportation costs that cannot be passed on to customers.
- •Regulatory changes (e.g., new FDA requirements) or widespread adoption of new purchasing models (e.g., GPOs favoring different suppliers) that undermine existing customer relationships.
MDLN Competitive Moat Analysis
Sign up to see competitive advantages
MDLN Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (Insufficient data to determine strong bullish or bearish retail sentiment for this recently public entity).
Institutional Sentiment
Positive (6 Buy/Outperform/Overweight ratings, 0 Sell ratings, with 23 analysts covering and providing price targets, median $50.0).
Insider Activity (Form 4)
Medline Inc. itself is not selling shares and receives no proceeds from the upsized secondary offering of 72,554,594 shares priced at $37.00/share on May 21, 2026; existing shareholders are monetizing their positions.
Options Flow
Normal options activity (No specific unusual options activity or put/call ratio trends were provided in the research).
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026 earnings).
Surprise Probability
Medium (No consensus EPS/revenue estimates provided in the research, making a definitive probability difficult to ascertain, but Q1 showed mixed results).
Historical Earnings Pattern
Too new to the public market to establish a consistent historical earnings reaction pattern. Q1 results led to an upsized secondary offering at a stable price, suggesting a mixed market reaction focused on liquidity.
Key Metrics to Watch
Competitive Position
Top Competitor
McKesson Medical-Surgical (MCK)
Market Share Trend
Stable (Research indicates growth with new and existing customers but no specific market share shift data provided. Operating in a highly competitive, consolidated market).
Valuation vs Peers
Medline appears to be trading at a premium EV/EBITDA multiple (implied 18.5x on current annualized EBITDA based on median analyst target) compared to established sector peers like Cardinal Health (CAH) and McKesson (MCK) which often trade in the 10-15x range for their distribution segments. This premium suggests an expectation of higher growth or margin improvement.
Competitive Advantages
- •Extensive, efficient distribution network and logistics infrastructure.
- •Broad and diverse product portfolio including own-brand manufacturing.
- •Deep, long-standing relationships with a wide range of healthcare providers.
- •Scale and purchasing power in a cost-sensitive industry.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive MDLN Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (Estimated August 2026): Positive surprise on gross margin stability or reversal of net income decline could re-rate the stock.
- •Resolution of FDA Warning Letter (H2 2026): Clearance from the FDA regarding device removal activities would alleviate regulatory overhang.
Medium-Term (6-18 months)
- •Major New Customer Contract Wins (Next 6-18 months): Securing large-scale contracts with major hospital systems, adding >$200M in annualized revenue, signaling continued market share capture.
- •Supply Chain Efficiency Improvements (Next 6-18 months): Demonstrated improvements in logistics or procurement that lead to a sustained 100-150 basis point increase in gross margin.
Long-Term (18+ months)
- •Expansion of Integrated Solutions (FY2027-2029): Successful rollout and adoption of higher-margin value-added services or technology platforms, increasing operating margin by 200+ basis points, shifting revenue mix.
- •Strategic International Market Entry/Expansion (FY2028+): Significant penetration into new high-growth international healthcare markets, contributing >15% of total revenue.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for MDLN?
- ✓
Watch quarterly gross margin; sustained improvement above 25.5% would be a strong positive signal.
- ✓
Monitor organic revenue growth from new customer implementations (quantified if possible in future earnings reports).
- ✓
Track net debt-to-Adjusted EBITDA ratio; reduction towards 2.5x or below would signal improving financial leverage.
Bull Case Analysis
Sign up free to see the bull case
Competing with MDLN
See how Medline Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Medline Inc MDLN | $48.7B | 0.5 | 50.5 | $29.1B | 3.3% | 8.1% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Medline Inc Makes Money
Medline Inc. operates as an integrated manufacturer and distributor of medical supplies, equipment, and solutions primarily to healthcare providers. It makes money by selling a vast array of medical products—from basic supplies like gloves and bandages to advanced surgical equipment and custom procedure kits—to hospitals, nursing homes, physician offices, and other care settings. The business model relies on its extensive distribution network, efficient logistics, and manufacturing capabilities to offer a comprehensive product portfolio and services, aiming for scale and cost advantages in a high-volume, competitive market.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Medline Inc (MDLN)?
As of May 23, 2026, Medline Inc has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Medline Inc?
Medline Inc's market capitalization is approximately $48.7B. The company operates in the Healthcare sector within the Medical Instruments & Supplies industry.
What ticker symbol does Medline Inc use?
MDLN is the ticker symbol for Medline Inc. The company trades on the NGM.
What is the risk level for MDLN stock?
Our analysis rates Medline Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of MDLN?
Medline Inc currently has a price-to-earnings (P/E) ratio of 50.5. This is above the market average, suggesting the stock may be priced for high growth expectations.
Is Medline Inc's revenue growing?
Medline Inc has reported revenue growth of 8.1%. The company is growing at a moderate pace.
Is MDLN stock profitable?
Medline Inc has a profit margin of 3.3%. The company is profitable but margins are modest.
How often is the MDLN DVR analysis updated?
Our AI-powered analysis of Medline Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 23, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MDLN (Medline Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.